FDA Recommends Updated COVID-19 Vaccines Due to Waning Effectiveness

The U.S. Food and Drug Administration (FDA) on June 3 recommended updating the formulation of the COVID-19 vaccines because of studies that indicate their effectiveness is worse against circulating variants of SARS-CoV-2, the virus that causes COVID-19.

“Available data,” the FDA staffers wrote, “suggest that updating the current formula of COVID-19 vaccines to more closely match currently circulating JN.1 lineage viruses is warranted for the anticipated 2024–2025 respiratory virus season in the U.S.”

Three COVID-19 vaccines are on the market in the United States, made by Pfizer-BioNTech, Moderna, and Novavax. The shots target the XBB.1.5 subvariant of SARS-CoV-2 and were cleared by regulators in the fall of 2023.

“While the majority of healthy, non-elderly adults may have minimal need for an updated vaccine, those who are elderly, immunocompromised, or have significant comorbidities clearly benefit from vaccination,” Dr. David Boulware, an infectious disease professor at the University of Minnesota’s Department of Medicine, told The Epoch Times via email. “A vaccine that most closely matches the currently circulating virus would be most protective.”

Related Stories

U.S. officials have said the COVID-19 vaccines could be updated annually—or even more frequently—in a system similar to the model used for influenza vaccines. The system is aimed at keeping up with newer variants.

The European Medicines Agency also advised updating the shots to target JN.1. “Adapting vaccines to target the JN.1 family of Omicron subvariants is adequate to ensure cross-reactivity against current dominant and emerging strains,” the agency said in a statement.

The FDA’s Vaccines and Related Biological Products Advisory Committee, a group of advisers, is set to meet on Wednesday to consider adopting the FDA’s recommendation.

Advisers will be presented with data from Pfizer, Moderna, and Novavax concerning how their vaccines are performing against JN.1 and KP.2, according to the FDA. The data were not included in the briefing document.

Jessica Adams, a former FDA officer, wrote on the social media platform X that in her opinion, “the FDA has neglected to require evidence of benefit-risk across all ages and prior-infected.”

She added, “Their approach of annual updates based entirely on strain surveillance and waning efficacy of the current version prematurely acts as if COVID vax for all is settled science when it isn’t.”

The FDA’s advisory committee has largely aligned with the agency during the COVID-19 pandemic, and its recommendations are typically taken up by the agency.

If the approval comes, the CDC would then weigh whether to say that certain populations, or virtually everybody, should get one of the updated vaccines. The agency has repeatedly recommended vaccinations during the pandemic, including among people with robust immunity from prior infection.

Low Uptake

Hundreds of millions of Americans took the original COVID-19 vaccines. Many of those people have not returned to receive any of the newer shots.

Just 22.5 percent of adults, and 14.4 percent of children, have received one of the currently available COVID-19 vaccines, according to CDC surveys.

Outside polls indicate reasons for not receiving one of the updated vaccines include concerns they’re not effective, and worries about side effects.

The vaccines have been confirmed to cause heart inflammation and other serious issues, with a small number of cases verified as leading to death.

The CDC currently recommends all Americans aged 6 months and older receive one of the vaccines, regardless of how many times a person has been infected and/or vaccinated in the past.